Manchester Financial’s XBiotech XBIT Stock Holding History

Manchester Financial’s Portfolio XBIT Stock Details XBIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-259	Closed	-$4K	–	663
2021 Q1	$4K	Buy	+259	New	+$4.83K	﹤0.01%	582

Other funds holding XBIT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Swiss National Bank Zurich, Switzerland $174B AUM 30.96% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 21.71% 1-Year Est. Return

Manchester Financial's XBIT Position: Q2 2021 in Review

Manchester Financial sold out of XBiotech (XBIT) in Q2 2021, closing a stake of 259 shares — an estimated $4K sold.

Manchester Financial first reported a position in XBIT in Q1 2021 and held it in 1 quarter. The position peaked at $4K in Q1 2021. 56 funds tracked by Wall St. Rank hold XBIT as of Q2 2021.

Manchester Financial reported no remaining XBiotech position as of Q2 2021 after selling out during the quarter.
Manchester Financial sold 259 XBiotech shares in Q2 2021, an estimated $4K.
Manchester Financial first reported a position in XBiotech in Q1 2021 and held it in 1 quarter.
Manchester Financial's XBiotech position peaked at $4K in Q1 2021.
56 funds tracked by Wall St. Rank held XBiotech as of Q2 2021.

Based on Manchester Financial's 13F filing for Q2 2021, filed 21 Jul 2021.